Authors

Leanne Burnham, PhD

Latest:

Dr. Burnham on Correlations Between Race and HER2 Positivity in Prostate Cancer

Leanne Burnham, PhD, discusses the correlation between HER2 positivity and race in patients with prostate cancer.

David R. Oveisi, MD

Latest:

Dr Oveisi on the Importance of Patient Counseling Prior to CAR T-Cell Therapy in Myeloma

David R. Oveisi, MD, discusses the importance of clear communication with patients prior to administering CAR T-cell therapy for multiple myeloma.

Santosh L. Saraf, MD

Latest:

Education Is a Personal Mission

Santosh Saraf, MD, changed his major 3 times as an undergrad at Penn State University, bouncing from premed to mathematics to marine biology before settling back into medicine.

Wojciech Jurczak, MD, PhD

Latest:

Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (≥75 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lymphoma

Dr. Wojciech Jurczak presents first disclosure results from the EPCORE DLBCL-3 trial, demonstrating that fixed-duration subcutaneous epcoritamab monotherapy achieves high response rates with a manageable safety profile in older, anthracycline-ineligible patients with previously untreated large B-cell lymphoma.

Neha S. Korde, MD

Latest:

Dr. Korde on Updated Findings From the Cassiopeia Trial in Multiple Myeloma

Neha S. Korde, MD, hematologist, Memorial Sloan Kettering Cancer Center, discusses key updates to the phase 3 Cassiopeia study (NCT02541383) in multiple myeloma.

Yuan Yuan, MD, PhD

Latest:

Dr Yuan on the Evolving Landscape of ADCs in HER2+ Breast Cancer

Yuan Yuan, MD, PhD, discussed the evolving landscape of therapeutic targets and payloads for ADCs in HER2-positive breast cancer.

Rami Komrokji, MD

Latest:

Closing Perspectives on R/R AML Treatment Advances

Panelists discuss future perspectives on the role of menin inhibitors in the treatment of acute lymphoblastic leukemia (AML), exploring potential advancements and clinical implications.

Stephen L. Chan, MD, The Chinese University of Hong Kong

Latest:

Real-World (RW) Systemic Treatment Patterns in US Patients (PTS) With Hepatocellular Carcinoma (HCC) 2020–2022

Stephen Chan, MD, presents real-world data from a systemic review of treatment patterns in the United States of patients with hepatocellular carcinoma from 2020 to 2022.

James Bussel, MD

Latest:

Key Takeaways From Discussion

Physicians share key takeaways from the discussion on diagnosis and treatment of immune thrombocytopenia.

R. Katie Kelley, MD

Latest:

FGFRi-Related Stomatitis and Dry Mouth Impacting Patient Quality of Life

Many patients with cholangiocarcinoma being treated with FGFRi will experience stomatitis and dry mouth, but there are strategies that can help.

Benjamin L. Schlechter, MD

Instructor, Medicine, Harvard Medical School and an attending Physician, Medical Oncology, Dana-Farber Cancer Institute.

Latest:

Dr Schlechter on the Safety of Botensilimab Plus Balstilimab in Pretreated MSS CRC

Benjamin L. Schlechter, MD, discusses safety with botensilimab plus balstilimab in MSS CRC.

Katie Joyner, Myeloma Patients Europe

Latest:

Impact of Clinical Trials on the Management of Multiple Myeloma

Continuing its discussion on clinical trials in multiple myeloma, the panel emphasizes the impact that data may have on the real-world treatment landscape.

Douglas W. Sborov, MD, MS

Latest:

Overview of PERSEUS, IsKia, and GMMG-HD7

Douglas Sborov, MD, discusses a brief overview of key clinical trials, including PERSEUS, IsKia, and GMMG-HD7, highlighting their implications for the treatment of patients with NDMM.

Rachel Layman, MD

Latest:

What is on the Horizon for Adjuvant Therapy in Early-Stage Breast Cancer?

Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.

Richard D. Carvajal, MD, Columbia University Irving Medical Center

Latest:

Future Management of Uveal Melanoma

The next steps in research investigating best practices using novel therapies such as tebentafusp as treatment for uveal melanoma.

Terri Parker, MD

Latest:

Dr. Parker Discusses the Importance of Optimizing Treatment in Multiple Myeloma

Terri Parker, MD, discusses considerations to optimize treatment in multiple myeloma.

Peter Voorhees, MD, Atrium Health Levine Cancer Institute

Latest:

Novel Therapies Under Study for Triple-Class Refractory Multiple Myeloma

Novel therapies in clinical development to improve outcomes for patients with triple-class refractory multiple myeloma.

Gerhard Hildebrandt, MD, FACP

Teresa Petrella, MD, MHSc, FRCPC

Teresa Petrella, MD, MHSc, FRCPC, is a medical oncologist at the Sunnybrook Odette Cancer Centre in Toronto, Canada, and an associate professor at the University of Toronto.

Latest:

Dr Petrella on Selecting Frontline Therapy in Metastatic Melanoma

Teresa Petrella, MD, MHSc, FRCPC, discusses considerations in selecting frontline therapy for patients with metastatic melanoma.

Sangeeta Goswami, MD, PhD

Sangeeta Goswami, MD, PhD, of the Department of Genitourinary Medical Oncology, Division of Cancer Medicine, of The University of Texas MD Anderson Cancer Center

Latest:

Dr. Goswami's Oncology Journey: Patient-centric Science and Mentorship Stories

Sangeeta Goswami, MD, PhD, discusses her career focused in genitourinary cancers, with a focus on patient-centric science and shares mentorship stories along the way.